Home › Uterine Cancer › NCT05049538
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * Women age 18 years and older * Histologic diagnosis of endometrial cancer * Candidate for primary surgical treatment or has recently had prior primary surgery * Willing and able to provide informed consent Exclusion Criteria: Patients who have received prior treatment including chemotherapy or radiation therapy for endometrial cancer. Prior hormonal therapy for the treatment of endometrial cancer is allowed. Patients with prior primary surgery will be allowed to enroll in this trial if the patient has not received any chemotherapy or radiation at the time of enrollment. Note: patients with a history of other cancers may be enrolled after discussion with the PI if it is determined that they are at low risk for recurrence or metastasis.
About the study
This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and storing samples of blood and tissue from patients with endometrial cancer to study in the laboratory may help doctors learn how the cells in the blood may change during treatment for uterine cancer.
What is being tested
- Biospecimen Collection (procedure)
- Liquid Biopsy (procedure)
- Pap Smear (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 1,000 · Started: Jun 18, 2019
Contact the study team
- Pamela T Soliman, MD · Phone: 713-745-2352
Official record on ClinicalTrials.gov — NCT05049538
Locations in the U.S.
| Texas | M D Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.